This week, Andreessen Horowitz said it’s launching a fund dedicated to investments in bioinformatics and “beyond the pill” technology. The venture capital firm had already gotten its feet wet with investments in these areas, but a dedicated fund is something new and indicates an interest in ramping up its strategy. With its fund, the firm could make a big impact. Here are some insights on some challenges and opportunities in these areas and some companies the firm should consider.
First of all, it’s worth noting some of the health and life science IT companies that Andreessen Horowitz have invested in so far. It’s only a handful to date:
{iframe}http://medcitynews.com/2015/11/andreessen-horowitz-investments/?utm_source=MedCity+News+Subscribers&utm_campaign=2741e21d1a-MCN+Daily+Email&utm_medium=email&utm_term=0_5092836c41-2741e21d1a-408826397{/iframe}